IRulya Therapeutics (QNCX) EGM 2026 summary

Opening remarks and agenda

• Meeting called to order at 11:00 a.m. ET on October 6, 2026; polls opened for six proposals, with voting available by webcast and previously submitted proxies included in the tally.

• Notice mailed on or about August 26, 2026 to stockholders of record as of August 24; inspector confirmed a quorum.

Specific resolutions to be voted on

• Proposal 1 sought approval for common shares issued upon Series C Preferred conversion and exercise of pre-funded warrants and/or PIPE options, including issuance exceeding 20% and a change of control under Nasdaq rules.

• Proposal 2 sought approval for common shares issued upon conversion of PIPE preferred shares and exercise of PIPE warrants under Nasdaq Rule 5635(d).

• Proposal 3 sought to increase authorized common shares from 250 million to 275 million.

• Proposals 4 and 5 sought approval of the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.

• Proposal 6 sought authority to adjourn or postpone the meeting, if needed, to continue soliciting votes on proposals 1, 2, and/or 3.

Discussions on mergers, acquisitions, or other significant changes

• Proposal 1 tied the preferred conversion and warrant/option exercises to a change of control, together with certain management and board changes.